Claims for Patent: 6,472,181

Summary for Patent: 6,472,181

Title:	Hybrid matrix implants and explants
Abstract:	An implantable device having a body of matrix material made up of insoluble collagen fibrils, and disposed therewithin (a) a plurality of vertebrate cells; and (b) a plurality of microspheres each of which consists primarily of one or more of the following materials: collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, or glass.
Inventor(s):	Mineau-Hanschke; Rochelle (Waltham, MA)
Assignee:	Transkaryotic Therapies, Inc. (Cambridge, MA)
Application Number:	09/312,246
Patent Claims:	1. A method of producing a polypeptide in vitro, comprising: providing a composition comprising a body of matrix material comprising insoluble collagen fibrils, there being embedded within the body of matrix material (a) a plurality of cultured vertebrate cells which express the polypeptide and (b) a plurality of microspheres; maintaining the composition under conditions whereby the cultured vertebrate cells express and secrete the polypeptide; contacting the composition with a liquid such that the cells secrete the polypeptide into the liquid; and obtaining the polypeptide from the liquid. 2. The method of claim 1, wherein the cultured vertebrate cells are genetically engineered to express the polypeptide. 3. The method of claim 2, wherein the polypeptide is selected from the group consisting of enzymes, hormones, cytokines, colony stimulating factors, vaccine antigens, antibodies, clotting factors, regulatory proteins, transcription factors, receptors, and structural proteins. 4. The method of claim 2, wherein the polypeptide is an angiogenesis factor. 5. The method of claim 1, wherein the composition is anchored to a surface and is bathed by the liquid. 6. The method of claim 1, wherein the composition floats freely in the liquid. 7. The method of claim 1, wherein the cultured vertebrate cells are selected from the group consisting of adipocytes, astrocytes, cardiac muscle cells, chondrocytes, endothelial cells, epithelial cells, fibroblasts, gangliocytes, glandular cells, glial cells, hematopoietic cells, hepatocytes, keratinocytes, myoblasts, neural cells, osteoblasts, pancreatic beta cells, renal cells, smooth muscle cells, striated muscle cells, and precursors of any of the above. 8. The method of claim 1, wherein the cultured vertebrate cells are human cells. 9. The method of claim 1, wherein the cultured vertebrate cells are transfected cells containing exogenous DNA encoding a medically useful polypeptide. 10. The method of claim 9, wherein the polypeptide is selected from the group consisting of human growth hormone, Factor VIII, Factor IX, erythropoietin, and insulin. 11. The method of claim 1, wherein the cultured vertebrate cells are transfected cells containing exogenous DNA which includes a regulatory sequence that activates expression of a gene encoding a medically useful polypeptide, said gene being endogenous to said vertebrate cells both prior to and after they are transfected. 12. The method of claim 11, wherein the polypeptide is selected from the group consisting of human growth hormone, Factor VIII, Factor IX, erythropoietin, and insulin. 13. The method of claim 1, wherein the polypeptide is selected from the group consisting of alpha-1 antitrypsin, calcitonin, glucocerebrosidase, low density lipoprotein (LDL) receptor, IL-2 receptor, globin, immunoglobulin, catalytic antibodies, the interleukins, insulin-like growth factor 1 (IGF-1), parathyroid hormone (PTH), leptin, the interferons, the nerve growth factors, basic fibroblast growth factor (bFGF), acidic FGF (aFGF), epidermal growth factor (EGF), endothelial cell growth factor, platelet derived growth factor (PDGF), transforming growth factors, endothelial cell stimulating angiogenesis factor (ESAF), angiogenin, tissue plasminogen activator (t-PA), granulocyte colony stimulating factor (G-CSF), and granulocyte-macrophage colony stimulating factor (GM-CSF). 14. The method of claim 1, wherein the microspheres are beads of type I collagen. 15. The method of claim 1, wherein the matrix material additionally comprises a substance selected from the group consisting of a second type of collagen, agarose, alginate, fibronectin, laminin, hyaluronic acid, heparan sulfate, dermatan sulfate, sulfated proteoglycans, fibrin, elastin, and tenascin. 16. The method of claim 1, additionally comprising noncollagen fibers dispersed within the body of matrix material. 17. The method of claim 16, wherein the noncollagen fibers comprise a material selected from the group consisting of nylon, dacron, polytetrafluoroethylene, polyglycolic acid, polylactic/polyglycolic acid mixture, polystyrene, polyvinylchloride copolymer, cat gut, cotton, linen, polyester and silk. 18. The method of claim 1, wherein each of the plurality of microspheres consists primarily of one or more substances selected from the group consisting of collagen, polystyrene, dextran, polyacrylamide, cellulose, calcium alginate, latex, polysulfone, and glass. 19. The method of claim 1, wherein the microspheres have a diameter between approximately 0.1 and approximately 2 mm. 20. The method of claim 1, wherein the collagen in the matrix material is type I.

Details for Patent 6,472,181

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2015-10-25